These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10397500)

  • 21. 1-aryl-4-[(5-methoxy-1,2,3, 4-tetrahydronaphthalen-1-yl)alkyl]piperazines and their analogues: influence of the stereochemistry of the tetrahydronaphthalen-1-yl nucleus on 5-HT1A receptor affinity and selectivity versus alpha1 and D2 receptors. 5.
    Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
    J Med Chem; 1999 Feb; 42(3):490-6. PubMed ID: 9986719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MP-3022, a new putative antagonist at pre- and postsynaptic 5-HT1A receptors.
    Przegaliński E; Filip M; Bijak M; Wedzony K; Budziszewska B; Tokarski K; Maćkowiak M; Fijał K
    Pol J Pharmacol; 1996; 48(1):13-22. PubMed ID: 9112623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological analysis of the hypothermic effects of NAN-190 and its analogs, postsynaptic 5-HT1A receptor antagonists, in mice.
    Wesołowska A; Borycz J; Paluchowska MH; Chojnacka-Wójcik E
    Pol J Pharmacol; 2002; 54(4):391-9. PubMed ID: 12523493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effect of Carboxamide/Sulfonamide Replacement in Arylpiperazinylalkyl Derivatives on Activity to Serotonin and Dopamine Receptors.
    Kowalski P; Śliwa P; Satała G; Kurczab R; Bartos I; Zuchowicz K
    Arch Pharm (Weinheim); 2017 Oct; 350(10):. PubMed ID: 28846141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An efficient synthesis of 5-bromo-2-methoxy-6-methylaminopyridine-3carboxylic acid.
    Hirokawa Y; Horikawa T; Kato S
    Chem Pharm Bull (Tokyo); 2000 Dec; 48(12):1847-53. PubMed ID: 11145130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1-Aryl-4-(4-succinimidobutyl)piperazines and their conformationally constrained analogues: synthesis, binding to serotonin (5-HT1A, 5-HT2A, 5-HT7), alpha1-adrenergic, and dopaminergic D2 receptors, and in vivo 5-HT1A functional characteristics.
    Bojarski AJ; Paluchowska MH; Duszyńska B; Kłodzińska A; Tatarczyńska E; Chojnacka-Wójcik E
    Bioorg Med Chem; 2005 Mar; 13(6):2293-303. PubMed ID: 15727878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analogues of the 5-HT1A serotonin antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine with reduced alpha 1-adrenergic affinity.
    Raghupathi RK; Rydelek-Fitzgerald L; Teitler M; Glennon RA
    J Med Chem; 1991 Aug; 34(8):2633-8. PubMed ID: 1652026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.
    Ofori E; Onyameh EK; Gonela UM; Voshavar C; Bricker B; Swanson TL; Eshleman AJ; Schmachtenberg JL; Bloom SH; Janowsky AJ; Ablordeppey SY
    Eur J Med Chem; 2021 Mar; 214():113243. PubMed ID: 33582388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. S 15535: a highly selective benzodioxopiperazine 5-HT1A receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectively.
    Millan MJ; Rivet JM; Canton H; Lejeune F; Gobert A; Widdowson P; Bervoets K; Brocco M; Peglion JL
    Eur J Pharmacol; 1993 Jan; 230(1):99-102. PubMed ID: 8381359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New sigma and 5-HT1A receptor ligands: omega-(tetralin-1-yl)-n-alkylamine derivatives.
    Berardi F; Colabufo NA; Giudice G; Perrone R; Tortorella V; Govoni S; Lucchi L
    J Med Chem; 1996 Jan; 39(1):176-82. PubMed ID: 8568804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors.
    Chłoń-Rzepa G; Zagórska A; Bucki A; Kołaczkowski M; Pawłowski M; Satała G; Bojarski AJ; Partyka A; Wesołowska A; Pękala E; Słoczyńska K
    Arch Pharm (Weinheim); 2015 Apr; 348(4):242-53. PubMed ID: 25773907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of mixed D2/5-HT1A activity of N-heteroarylmethyl-N-phenylpiperazines, N-heteroarylethyl-N-phenylpiperazines and N-heteroarylpropyl-N-phenylpiperazines.
    Roglić G; Dukić-Stefanović S; Andrić D; Kostić-Rajacić S; Soskić V
    Pharmazie; 2001 Oct; 56(10):803-7. PubMed ID: 11683128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-activity relationship studies of CNS agents, Part 31: Analogs of MP 3022 with a different number of nitrogen atoms in the heteroaromatic fragment--new 5-HT1A receptor ligands.
    Paluchowska MH; Dereń-Wesołek A; Mokrosz JL; Charakchieva-Minol S; Chojnacka-Wójcik E
    Arch Pharm (Weinheim); 1996 Oct; 329(10):451-6. PubMed ID: 8933747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis of new 1,2,3-benzotriazin-4-one-arylpiperazine derivatives as 5-HT1A serotonin receptor ligands.
    Caliendo G; Fiorino F; Grieco P; Perissutti E; Santagada V; Severino B; Bruni G; Romeo MR
    Bioorg Med Chem; 2000 Mar; 8(3):533-8. PubMed ID: 10732969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299.
    Johansson L; Sohn D; Thorberg SO; Jackson DM; Kelder D; Larsson LG; Rényi L; Ross SB; Wallsten C; Eriksson H; Hu PS; Jerning E; Mohell N; Westlind-Danielsson A
    J Pharmacol Exp Ther; 1997 Oct; 283(1):216-25. PubMed ID: 9336327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.
    Vangveravong S; Zhang Z; Taylor M; Bearden M; Xu J; Cui J; Wang W; Luedtke RR; Mach RH
    Bioorg Med Chem; 2011 Jun; 19(11):3502-11. PubMed ID: 21536445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo.
    Millan MJ; Rivet JM; Audinot V; Gobert A; Lejeune F; Brocco M; Newman-Tancredi A; Maurel-Remy S; Bervoets K
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1418-27. PubMed ID: 7791116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
    Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.